Archive for December, 2015
Military’s best friend – they are also our “Hero’s”
Posted in Uncategorized on December 15, 2015| Leave a Comment »
12/9 Update to Targeted Acqui-Hire: E-Commerce Division of Fortune 100 Seeking Acqui-Hire for World Wide E-Commerce Development
Posted in Uncategorized, tagged Acqui-Hire - New York City, Gerbsman Partners, steven r gerbsman on December 9, 2015| Leave a Comment »
Good afternoon
As an update to the Acqui-Hire transaction outlined below, I have highlighted specific background areas of interest for technology personnel in the New York City area.
Roles:
1. Web engineers with experience in Javascript development like React, Angular.js and node.js
2. Backend engineers with experience in API development using languages like Python and Frameworks like Django
3. Data engineers with experience doing database development and including some big data capabilities
4. Operation engineers with experience using Amazon Web Services and enabling continuous integration and delivery for teams
Candidates for the Acqui-Hire transaction may be distressed or under-performing companies in your portfolio.
If there are any candidates, this may be a potential deal structure to recover some value from the assets and the key technology personnel would have a significant opportunity going forward, if qualified.
I am available to discuss.
As always, thank you for your courtesy in reviewing.
Best
Steve

San Francisco – December 2015 Targeted Acqui-Hire Transaction: The acquirer is looking for an experienced development team with a strong background in web app development and e-Commerce that wishes to collaborate under the umbrella of a global brand.
Objective/Capabilities of Team
The acquirer is looking for an experienced development team with a strong background in web, e-commerce and mobile app development that wishes to collaborate under the umbrella of a global brand. The target team will include experienced practitioners with design/UX, product/project management, system architecture, development, testing/QA and consumer product experience and be capable of hitting the ground running. The target team must be able to take a concept, scope and build an MVP, and then be able to rapidly iterate to deliver innovative solutions that will transform the consumer experience centered around major premium brands for consumers from around the world.
Opportunity
A newly created ventures group imbedded within a larger global organization has received a mandate to build disruptive businesses and power revenue through innovative technology. This venture group’s e-commerce team is charged with building a global consumer business that combines commerce, content, and community in new ways, so as to improve the entire category experience from education and selection to purchase and consumption.
The target technology company/team will join a NYC team in order to power this innovative vision. The target team will collaborate with others from around the world to develop deployable “white label” solutions that allow for a quick pilot and phased roll-out of new ideas.
Compensation Package
Competitive, industry compensation and stock incentives will be awarded commensurate with experience and potential for success. The philosophy of this Fortune 100 enterprise is centered around the delivery of results, with upside and bonuses tied to performance. Senior management will be available to discuss this significant opportunity.
For additional information and to meet with the senior executives, please call Steven R. Gerbsman, information below.
About Gerbsman Partners
Gerbsman Partners focuses on maximizing enterprise value for stakeholders and shareholders in under-performing, under-capitalized and under-valued companies and their Intellectual Property. Since 2001, Gerbsman Partners has been involved in maximizing value for 91 Technology, Medical Device, Life Science, Solar, Fuel Cell, Cyber/Data Security and Digital Marketing companies and their Intellectual Property and has restructured/terminated over $810 million of real estate executory contracts and equipment lease/sub-debt obligations. Since inception in 1980, Gerbsman Partners has been involved in over $2.3 billion of financings, restructurings and M&A transactions.
Gerbsman Partners has offices and strategic alliances in San Francisco, Boston, New York, Washington, DC, McLean, VA, Europe and Israel.
Is The Cleantech Bubble Over? The Reality Of Solar Economics by Michael Lynch – Forbes Magazine
Posted in Uncategorized, tagged Cleantech Bubble, Forbes, Michael Lynch, Solar Economics on December 7, 2015| Leave a Comment »
Is The Cleantech Bubble Over? The Reality Of Solar Economics
Opinions expressed by Forbes Contributors are their own.
In an earlier post, I noted that advocates of solar energy in particular tend to avoid talking about the cost of the electricity produced by focusing on the fact that costs are dropping, or that prices are sometimes low, or simply pointing to the large increase in installations as evidence of success. Unfortunately, the message seems to be that advocates of solar power are either ignorant of, or willfully ignoring, real world developments.
Consider: two prominent solar companies have run into serious difficulties. Hanergy Thin Film Solar has seen its stock suspended from trading and SunEdison has seen its stock price fall 85% recently. Both had been industry darlings and provided strong gains to ETFs that held them—those same ETFs now suffering the price of their exuberance.
And despite claims that government subsidies are unimportant, solar providers are reeling from cutbacks in government aid. Projects in the UK have been cancelled as the offered prices for power were cut, and hundreds laid off. Supporters make it sound as if the government is working against the industry, rather than cutting assistance, apparently not wishing to admit the technology remains uncompetitive.
Similarly, in Japan and Germany, solar success has been widely hailed as worthy of emulation, with comments such as “And yet a combination of canny regulation and widespread public support for renewables have made Germany an unlikely leader in the global green-power movement.”
But those who are not solar power activists have a different view, noting that solar remains very expensive and that rising amounts of unpredictable and highly volatile generation are adding to utility costs. This has led to pushback from utilities, who feel that solar panel owners should share those costs and that restrictions should be placed on net metering. Such pressure will increase in the US as renewable mandates raise the market share of solar power in some states.
The industry is starting to be affected, as British Solar firm Mark Group has declared bankruptcy, SolarCity’s stock price has been under pressure, and two large yieldcos, designed to use innovative financing to develop solar capacity, have seen their market value crater.
Evolution Venture Partners – member of Gerbsman Partners Board of Intellectual Capital – facilitates $50 Million Investment for Precision Biologics
Posted in Uncategorized, tagged Evolution Partners, Gerbsman Partners Board, Philip Taub, Precision Biologics on December 4, 2015| Leave a Comment »
Evolution Venture Partners facilitates $50 Million Investment for Precision Biologics
Los Angeles – October 19, 2015 — Evolution Venture Partners announces that it acted as financial advisor to Precision Biologics, Inc., a privately held, biopharmaceutical company developing tumor-specific monoclonal antibodies (mAbs) and companion diagnostics to treat solid-tumor cancers. NantWorks, LLC, and it’s ecosystem of next generation healthcare entities focusing on the discovery and development of immunology-based innovative treatments for diseases at the molecular level, today announced a $50 million equity investment in Precision Biologics, Inc.
“Evolution Venture Partners was invaluable to Precision Biologics in this transaction. Evolution’s knowledge, professionalism and their disciplined process allowed us to find the ideal investment partner. Their impressive set of relationships in the financial community as well as their understanding of the nuances of our company and knowledge in the biotech space made them the perfect advisor for us,” said Philip M. Arlen, M.D., chief executive officer of Precision Biologics.
“Precision Biologics has a promising novel pipeline of therapeutic antibody candidates that target advanced pancreatic and colorectal cancers in clinical trials, as well as a companion diagnostics program that determines which patients are candidates to receive treatment,” said Patrick Soon-Shiong, M.D., founder and chief executive officer of NantWorks. “Based on a proprietary library of cancer vaccines, antigens and antibodies, the company has developed a portfolio of truly unique antibody therapies, which activate an immune response that are tumor and disease specific. The mission at Nantworks is the pursuit of neo-epitope driven immunotherapy for cancer. This investment furthers our mission to treat the biology of cancer, independent of the anatomy, and avoid the devastating toxic effects of standard chemotherapy while activating mankind’s innate immune protective system. With a highly experienced management and scientific team, the company will complement NantWorks approach to this paradigm shift in the molecular interrogation and treatment of cancer.”
Precision Biologics is leveraging its proprietary library of cancer vaccines to accelerate innovation. By marrying this platform with breakthrough diagnostic and immunotherapy technologies available at Nantworks and NantOmics, the company is now able to develop compounds that could change the way we detect and treat cancer. For its lead therapeutic antibody candidate, the company recently completed accrual to a Phase 2a clinical trial for advanced pancreatic and colorectal cancer. In addition a multi-center randomized Phase 2b trial for advanced pancreatic cancer is currently enrolling patients at several well-known academic medical centers in the US. The therapeutic antibody candidate for pancreatic cancer has demonstrated promising early phase 2 data and received Orphan Drug status. The company’s pipeline also includes two additional novel, proprietary antibodies, both of which bind to tumor-specific antigens found in pancreatic, colorectal and several other types of cancer.
“The antibodies we are developing are derived from proprietary cancer vaccines isolated from surgically removed human tumors,” said Dr. Arlen. “The investment from Nantworks provides the resources that will allow for the continued development of our lead novel antibodies for pancreatic and colorectal cancers, as well as the identification of additional novel antibodies for other cancers. We are extremely pleased and fortunate to collaborate and be associated with Dr. Soon-Shiong and the NantWorks family of companies. We share a vision to improve cancer care through precision medicine.”
Evolution Venture Partners acted as sole financial advisor to Precision Biologics in connection with this transaction.
About Evolution Venture Partners
Evolution Venture Partners is an investment banking and merchant banking boutique focused on biotechnology, life sciences and healthcare companies & specializes in capital raising, mergers & acquisitions, and strategic partnering. Evolution Venture Partners provides insightful strategic advice to healthcare companies with special emphasis on drug development therapeutic, medical device therapeutic and diagnostics companies. Their network of strong relationships with venture capital funds, hedge funds, crossover funds and corporate strategics empowers healthcare companies to achieve transformative outcomes. For more information go to http://www.evovp.com.
About Precision Biologics
Founded in February 2012 and commencing business in late September 2012, Precision Biologics is a clinical stage biotechnology corporation focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer. The company’s antibody drug candidates and diagnostics are designed to detect and target the tumor without destroying healthy cells. Precision Biologics is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials. By marrying this platform with today’s breakthrough technologies, the company is developing antibody therapeutics that could change the way cancer is detected and treated.
About NantWorks
NantWorks, LLC, founded by renowned physician scientist and inventor of the first human nanoparticle chemotherapeutic agent Abraxane®, Dr. Patrick Soon-Shiong, is the umbrella organization for the following entities: NantHealth, NantMobileHealth, NantOmics, NantBio, NantCell, NantPharma, NantCapital and NantCloud. Fact-based and solution-driven, each of NantWorks’ division entities operates at the nexus of innovation and infrastructure.
The core mission of NantWorks is convergence and a systems approach to human biology: to develop and deliver a diverse range of technologies that accelerates innovation, broaden the scope of scientific discovery, enhance ground-breaking research, and improve healthcare treatment for those in need.
NantWorks is building an integrated fact-based, genomically and proteomically -informed, personalized approach to the delivery of care and the development of next generation diagnostics and therapeutics for life threatening diseases such as Cancer, Infectious Diseases and Alzheimer’s. For more information please www.nantworks.com and follow Dr. Soon-Shiong on Twitter@solvehealthcare.
12/3 Update to the Bidding Process for “Date Certain M&A” of LifeNexus, Inc., its Assets and Intellectual Property -with Asset Purchase Agreement
Posted in Uncategorized, tagged Date Certain M&A Process, Gerbsman Partners, LifeNexus, steven r gerbsman on December 3, 2015| Leave a Comment »

The Bidding Process, Procedures for the Sale of certain Assets and Intellectual Property of LifeNexus, Inc..
Further to Gerbsman Partners previous e-mail and sales letter of November, 2015, regarding the sale of certain assets of LifeNexus, Inc.,(LifeNexus), I am attaching the detailed sales letter and attachments A, B,C & D. (NDA, Patent and Trademark lists and iChip Health Record pdf) and the Asset Purchase Agreement (“APA”). Ken, Jim and I will be following up to review the Bidding Process, schedule due diligence meetings and answer any questions.
Gerbsman Partners has been retained by LifeNexus, Inc. to solicit interest for the acquisition of all or substantially all of LifeNexus’s assets, including its Intellectual Property (“IP”), in whole or in part (collectively, the “Life Nexus Assets”).
Any and all the assets of Life Nexus will be sold on an “as is, where is” basis and will be subject to “The Bidding Process for Interested Buyers”, outlined below.
Prior to the bid date of December 22, 2015, and after you receive the draft “APA” I would encourage all interested parties to have their counsel speak with Michael Sebree, Esq. of the Donahue law firm counsel to LifeNexus. He is available to discuss any questions or comments of a legal nature relating to the transactions contemplated by the APA. Michael is available at 510 451 3300 office, msebree@donahue.com.
Please see at the end of the email a “testimonial” from a LifeNexus user at New Mexico Health Connections. Martin Hickey, CEO, is available to speak with any potential interested party. Please call Steve Gerbsman to make an introduction.
The Bidding Process for Interested Buyers
Interested and qualified parties will be expected to sign a nondisclosure agreement (attached hereto as Attachment A) to have access to key members of the management and intellectual capital teams and the due diligence “war room” documentation (the “Due Diligence Access”). Each interested party, as a consequence of the Due Diligence Access granted to it, shall be deemed to acknowledge and represent (i) that it is bound by the bidding procedures described herein; (ii) that it has an opportunity to inspect and examine the LifeNexus Assets and to review all pertinent documents and information with respect thereto; (iii) that it is not relying upon any written or oral statements, representations, or warranties of Gerbsman Partners or LifeNexus, or their respective staff, agents, or attorneys; and (iv) all such documents and reports have been provided solely for the convenience of the interested party, and LifeNexus and Gerbsman Partners (and their respective, staff, agents, or attorneys) do not make any representations or warranties as to the accuracy or completeness of the same.
Following an initial round of due diligence, interested parties will be invited to participate with a sealed bid, for the acquisition of the LifeNexus Assets. Sealed bids must be submitted so that they are actually received by Gerbsman Partners no later than Tuesday, December 22, 2015 at 3:00 p.m. Mountain Time (the “Bid Deadline”) at Gerbsman Partners office, located at 211 Laurel Grove Avenue, Kentfield, CA 94904. Please also email steve@gerbsmanpartners.com with any bid.
Bids should identify those assets being tendered for in a specific and identifiable way.
Any person or other entity making a bid must be prepared to provide independent confirmation that they possess the financial resources to complete the purchase where applicable. All bids must be accompanied by a refundable deposit check in the amount of $200,000 (the refundable deposit will be held in LifeNexus’ legal counsel trust account). The winning bidder will be notified within 3 business days of the Bid Deadline. Unsuccessful bidders will have their deposits returned to them within 3 business days of notification that they are an unsuccessful bidder.
LifeNexus reserves the right to, in its sole discretion, accept or reject any bid, or withdraw any or all of the assets from sale. Interested parties should understand that it is expected that the highest and best bid submitted will be chosen as the winning bidder and bidders may not have the opportunity to improve their bids after submission.
LifeNexus will require the successful bidder to close within a 7 day period after they receive notice of their successful bid. Any or all of the assets of LifeNexus will be sold on an “as is, where is” basis, with no representation or warranties whatsoever.
All sales, transfer, and recording taxes, stamp taxes, or similar taxes, if any, relating to the sale of the LifeNexus Assets shall be the sole responsibility of the successful bidder and shall be paid by the successful bidder at the closing of the transaction.
For additional information, please see below and/or contact:
Steven R. Gerbsman
Gerbsman Partners
(415) 456- 0628
steve@gerbsmanpartners.com
Kenneth Hardesty
Gerbsman Partners
(408) 591-7528
ken@gerbsmanpartners.com
James Skelton
Gerbsman Partners
(949) 466-7303
jim@gerbsmanpartners.com
Testimonial From: Martin Hickey <martin.hickey@mynmhc.org>
Date: Wednesday, December 2, 2015 at 10:28 AM
To: “Steven R. Gerbsman” <steve@gerbsmanpartners.com>
Subject: Life Nexus
New Mexico Health Connections is a new health plan which started coverage in 2014. We currently have 35,000 members and will double and potentially triple that number by the end of 2016. We are a very aggressive, nimble and highly innovative organization. We began working with Life Nexus this September to pilot an implementation with a 300 physician medical group, Albuquerque Health Partners and carry that implementation to enroll all of our members by the end of 2016. Knowing that healthcare is finally becoming consumer centric and moving to smart technology, we looked at several firms to assist this rapidly growing trend, even here in New Mexico. We needed a technology that is affordable, flexible, highly innovative and, in particular understands physician and member adoption. We found the iChip technology and platform to be just that. We also did significant due diligence on the key developers of the platform in regards to their health IT experience, and as important, their knowledge and flexibility in working with physicians.
Most of my career has been working with and leading physicians. Their adoption of smart technology is key to any successful project such as Life Nexus is approaching. Again, the Life Nexus team’s ability to learn and flex their product to individual physician behavior was a key in our selection. As a highly experienced physician executive and CEO for over thirty years, I found the Life Nexus approach, team and technology to be vastly superior to any other vendor getting into the smart technology space. I am happy to discuss our thinking, experience and significant additional potential of Life Nexus should anyone wish to do so. I am hoping that the technology will continue as we, New Mexico Health Connections intend to grow to over 300,000 members in New Mexico over the next five years, as well as begin an expansion into Texas in 2018. We will also serve as the alpha project in smart technology for another 10 affiliated health plans in other states around the nation.
Martin Hickey, MD
CEO, New Mexico Health Connections
Chairman of the Board, The National Alliance of
State Health Co-operatives







